A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Oral Doses of Genz-682452 With a Pilot Investigation of Food Effect in Healthy Adult Male Subjects
Latest Information Update: 22 Mar 2022
At a glance
- Drugs Genz 682452 (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- Sponsors Sanofi
- 09 Apr 2014 New trial record